Ascletis Pharma Inc (2VJ) - Total Liabilities
Based on the latest financial reports, Ascletis Pharma Inc (2VJ) has total liabilities worth €132.26 Million EUR (≈ $154.63 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Ascletis Pharma Inc (2VJ) equity growth momentum to track the company's year-over-year net asset growth rate.
Ascletis Pharma Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how Ascletis Pharma Inc's total liabilities have evolved over time, based on quarterly financial data.
Ascletis Pharma Inc Competitors by Total Liabilities
The table below lists competitors of Ascletis Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CLARIVATE PLC
NYSE:CLVT
|
USA | $6.14 Billion |
|
ProAssurance Corporation
NYSE:PRA
|
USA | $4.25 Billion |
|
Gold.com, Inc.
NASDAQ:GOLD
|
USA | $3.27 Billion |
|
Jamieson Wellness Inc
TO:JWEL
|
Canada | CA$684.21 Million |
|
Zensar Technologies Limited
NSE:ZENSARTECH
|
India | Rs11.33 Billion |
|
Inno Laser Technology Co. Ltd.
SHE:301021
|
China | CN¥184.04 Million |
|
Via Transportation, Inc.
NASDAQ:VIA
|
USA | $101.19 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Ascletis Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Ascletis Pharma Inc (2VJ) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ascletis Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ascletis Pharma Inc (2016–2025)
The table below shows the annual total liabilities of Ascletis Pharma Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €132.26 Million ≈ $154.63 Million |
-16.51% |
| 2024-12-31 | €158.41 Million ≈ $185.20 Million |
+6.36% |
| 2023-12-31 | €148.94 Million ≈ $174.13 Million |
+27.13% |
| 2022-12-31 | €117.16 Million ≈ $136.97 Million |
+16.13% |
| 2021-12-31 | €100.89 Million ≈ $117.95 Million |
+18.10% |
| 2020-12-31 | €85.42 Million ≈ $99.87 Million |
-16.39% |
| 2019-12-31 | €102.17 Million ≈ $119.45 Million |
+1.98% |
| 2018-12-31 | €100.19 Million ≈ $117.13 Million |
-17.49% |
| 2017-12-31 | €121.42 Million ≈ $141.96 Million |
-4.53% |
| 2016-12-31 | €127.18 Million ≈ $148.69 Million |
-- |
About Ascletis Pharma Inc
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory … Read more